Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) ABRAXANE paclitaxel 100mg/20mL powder for injection (suspension) (Germany)
Section 19A approved medicine
(Approval lapsed) ABRAXANE paclitaxel 100mg/20mL powder for injection (suspension) (Germany)
Section 19A approval holder
Specialised Therapeutics Australia Pty Ltd ABN 73 124 031 241
Phone
1300 798 820
Approved until
Status
Expired
Medicines in short supply/unavailable
ABRAXANE nanoparticle albumin-bound paclitaxel 100 mg powder for injection (suspension) vial - AUSTR 133500
Indication(s)
- Metastatic Breast Cancer - ABRAXANE is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.
- Non-small Cell Lung Cancer - ABRAXANE, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation.
- Metastatic Adenocarcinoma of the Pancreas - ABRAXANE, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.